Study data boosts Renovo
RENOVO, the North West company pioneering drugs to reduce scarring and improve wound healing, has announced positive results of a trial into the use of its key product on children.
The Manchester said the study into anew formulation called Juvista Paediatric had proved that it was safe and also works. Further studies will now be undertaken.
The trial also confirmed that the existing adult formulation of Juvista, used in the ongoing EU Phase III trial, produces the most significant improvement in scar appearance compared to placebo treatment.
Renovo founder and chief executive Professor Mark Ferguson, said: “This trial has been extremely successful. Not only have we established that we have a new formulation that is suitable for further evaluation in children, ideally as a single administration, but we have also reconfirmed that the dose of Juvista in our ongoing EU Phase III trial (REVISE) was appropriately selected as it demonstrated the greatest level of efficacy”.
The first Juvista EU Phase III trial in scar revision surgery, which has involved more than 350 patients, should report data during the first half of 2011.
